Metabolism-Mediated FGF5 Association with Stroke: Based on Mendelian Randomization and Bioinformatics Analysis.

BACKGROUND

Stroke is the second leading cause of death and the third leading cause of disability worldwide. The role of fibroblast growth factor 5 (FGF5) in the occurrence and development of stroke remains unclear. We used bidirectional Mendelian randomization (MR) analysis to evaluate the mediating role of metabolites and causal association between inflammatory factors and stroke.

METHODS

We analyzed the stroke dataset from the FinnGen database (v11) (cases: 43,132; Control: 297,867). Data on metabolites and inflammatory factors were obtained from the genome-wide Association Studies (GWAS) catalog of the European Institute for Bioinformatics (EBI). Using expression data of FGF5 mRNA and protein in the Comprehensive Gene Expression Database (GEO) and clinical data, expression level and clinical relevance of FGF5 in stroke were explored. The protein-protein interaction (PPI) network of FGF5-related genes was constructed, and various bioinformatics analyses (including functional enrichment, immune infiltration analysis, etc) were conducted to evaluate its functional mechanism.

RESULTS

FGF5 was significantly associated with stroke risk (inverse variance weighting method (IVW): odds ratio (OR) = 1.052, 95% confidence interval (CI): 1.021-1.084, P<0.01). Mediation analysis indicated that inflammatory factors influenced stroke risk through the metabolites 1-palmitoyl-phosphoglycerol (GPG) [effect: 0.00462 (-0.0102, 0.001); mediated effect: 9.09% (-20.2%, 1.97%)], 1-stearoyl-2-arachidonoyl-phosphoethanolamine (GPE) [effect: 0.00274 (-0.00212, 0.0076); mediated effect: 5.39% (4.17%, 14.9%). Among them, the mediating effect of 1-palmitoyl phosphatidylglycerol (GPG) was not significant. Furthermore, FGF5 is associated with epithelial cell proliferation, peptidyl-tyrosine phosphorylation, CD4+ primary T cells and M0 macrophages.

CONCLUSION

This study, by integrating multiple omics methods, such as Mendelian randomization, expression profiling analysis, and bioinformatics, has for the first time established FGF5 as a novel potential biomarker for stroke risk. Inflammatory factors can mediate the molecular pathways of stroke occurrence through metabolites such as GPE. The value of FGF5 as a novel biomarker for the diagnosis/prognosis of stroke and the new mechanism of stroke-related metabolic regulatory network provide a theoretical basis for targeted intervention of stroke.